F Dx Advisors, Inc. Bei Gene, Ltd. Transaction History

F Dx Advisors, Inc.

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 03, 2022	SELL	$121.11 - $216.05 $280,854 - $501,019	-2,319 Closed	0 $0
Q1 2022 May 03, 2022	SELL	$146.52 - $269.56 $51,282 - $94,346	-350 Reduced 13.11%	2,319 $437,000
Q4 2021 Feb 01, 2022	SELL	$248.56 - $389.34 $15,410 - $24,139	-62 Reduced 2.27%	2,669 $723,000
Q3 2021 Oct 08, 2021	SELL	$249.6 - $403.14 $23,462 - $37,895	-94 Reduced 3.33%	2,731 $991,000
Q2 2021 Aug 05, 2021	SELL	$292.75 - $367.01 $14,052 - $17,616	-48 Reduced 1.67%	2,825 $970,000
Q1 2021 Apr 14, 2021	BUY	$260.64 - $382.12 $488,178 - $715,710	1,873 Added 187.3%	2,873 $1 Million
Q1 2021 Apr 13, 2021	SELL	$260.64 - $382.12 $474,104 - $695,076	-1,819 Reduced 64.53%	1,000 $348,000
Q4 2020 Feb 08, 2021	BUY	$221.31 - $316.61 $129,245 - $184,900	584 Added 26.13%	2,819 $728,000
Q3 2020 Nov 12, 2020	BUY	$189.18 - $286.44 $45,024 - $68,172	238 Added 11.92%	2,235 $640,000
Q2 2020 Jul 22, 2020	BUY	$123.9 - $195.41 $27,134 - $42,794	219 Added 12.32%	1,997 $376,000
Q1 2020 May 22, 2020	BUY	$121.84 - $173.19 $216,631 - $307,931	1,778 New	1,778 $219,000
Q1 2020 May 13, 2020	SELL	$121.84 - $173.19 $201,279 - $286,109	-1,652 Closed	0 $0
Q4 2019 Feb 12, 2020	SELL	$115.78 - $208.34 $7,178 - $12,917	-62 Reduced 3.62%	1,652 $274,000
Q3 2019 Nov 07, 2019	BUY	$120.61 - $148.29 $7,719 - $9,490	64 Added 3.88%	1,714 $210,000
Q2 2019 Jul 19, 2019	BUY	$113.99 - $146.86 $188,083 - $242,319	1,650 New	1,650 $205,000

249

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.5B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of F Dx Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on F Dx Advisors, Inc. with notifications on news.